Edgewise Therapeutics, Inc.
EWTX
Ранг среди акций
#4051
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Цена акции
$37.15
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$4.00B
Изменение (1 день)
-2.75%
Изменение (1 год)
146.68%
Страна
US
Торговля Edgewise Therapeutics, Inc. (EWTX)
Категория
Healthcare
EPS для Edgewise Therapeutics, Inc. (EWTX)
EPS по состоянию на June 2026 TTM: $-1.85
Согласно последним финансовым отчетам и цене акций Edgewise Therapeutics, Inc., текущий EPS компании (TTM) составляет $-1.85. В конце 2023 EPS компании составлял $-1.57, больше, чем показателю 2022 года, равному $-1.26.
История EPS компании Edgewise Therapeutics, Inc. с 2019 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
